Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM4B | O94953 | 1/20 | 0.33 |
| ▸ | KDM5C | P41229 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 3/20 | 0.31 |
| ▸ | ATRIP | Q8WXE1 | 3/20 | 0.31 |
| ▸ | NOS3 | P29474 | 2/20 | 0.30 |
| ▸ | NOS2 | P35228 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28705300 | 0.75 | KDM4A (0.33) | KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL1298647 | 0.75 | KDM4A (0.33) | KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL14485456 | 0.75 | KDM4A (0.33) | KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL6022428 | 0.69 | HCAR2 (0.37) | KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL1747899 | 0.68 | KDM4A (0.37) | KDM4AKDM4BKDM5CKDM5BNOS3 | |
| SCHEMBL4946889 | 0.68 | — | — | |
| SCHEMBL28694273 | 0.68 | — | — | |
| Hydrochloric Acid SCHEMBL3353320 | 0.67 | KDM4A (0.36) | KDM4AKDM4BKDM5CKDM5BNOS3 | |
| SCHEMBL1800839 | 0.67 | CDK5 (0.42) | — | |
| SCHEMBL1299475 | 0.65 | JMJD6 (0.30) | KDM4AKDM4BKDM5CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111961058-B | 4-amino-pyrrolotriazine derivatives, and preparation method and application thereof | 天津全和诚科技有限责任公司 | 2022-12-16 | — | — | CN | claimed |
| CN-112028892-B | Application of 4-amino-pyrrolotriazine derivative in preparation of anti-pulmonary fibrosis preparation | 天津全和诚科技有限责任公司 | 2022-12-16 | — | — | CN | claimed |
| CN-112028892-A | Application of 4-amino-pyrrolotriazine derivative in preparation of anti-pulmonary fibrosis preparation | 天津全和诚科技有限责任公司 | 2020-12-04 | — | — | CN | claimed |
| CN-111961058-A | 4-amino-pyrrolotriazine derivatives, and preparation method and application thereof | 天津全和诚科技有限责任公司 | 2020-11-20 | — | — | CN | claimed |
| CN-106974892-A | A kind of pharmaceutical composition containing 4 amino-pyrroles and triazine derivatives species kinase inhibitor and preparation method thereof | 亿腾药业（泰州）有限公司 | 2017-07-25 | — | — | CN | claimed |
| WO-2025090966-A1 | MEK INHIBITORS, ALONE OR IN COMBINATION WITH CDK4/5 INHIBITORS, FOR USE IN TREATING CANCER | VEVO THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2024245115-A1 | PREPARATION METHOD FOR PYRROLOTRIAZINE COMPOUND | 临海市华南化工有限公司 | 2024-12-05 | — | — | WO | disclosed |
| US-20240307427-A1 | REMDESIVIR COCRYSTAL, COMPOSITIONS AND METHODS THEREOF | VERSITECH LIMITED (CN) | 2024-09-19 | — | — | US | disclosed |
| CN-118638154-A | Ruidexiwei eutectic, composition and method thereof | 港大科桥有限公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-112262139-B | Aminopyrrolotriazines as kinase inhibitors | 百时美施贵宝公司 | 2023-07-25 | — | — | CN | disclosed |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-04 | — | — | US | disclosed |
| CN-101466710-A | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2009-06-24 | — | — | CN | disclosed |
| CN-101365454-A | Substituted 4-amino-pyrrolotriazine derivatives for the treatment of hyperproliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2009-02-11 | — | — | CN | disclosed |
| CN-101365454-A | Substituted 4-amino-pyrrolotriazine derivatives for the treatment of hyperproliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2009-02-11 | — | — | CN | disclosed |
| EP-1957077-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer HealthCare LLC (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007064883-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC. (US) | 2007-06-07 | — | — | WO | disclosed |
| CN-1882739-A | Method for improving color depth | CIBA SC HOLDING AG (CH) | 2006-12-20 | — | — | CN | disclosed |
| CN-1678285-A | Dyeing method for porous material | CIBA SC HOLDING AG (CH) | 2005-10-05 | — | — | CN | disclosed |
| CN-1556839-A | Cationic reactive dyes | 西巴特殊化学品控股有限公司 | 2004-12-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | RIPK1, RIPK2, RIPK4 | KDM4A 2848/4885KDM4B 3630/4885KDM5C 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.